Rising Penn star Saar Gill gets funding for a next-gen CAR-T startup, adding a new weapon to the mix

John Carroll

Editor & Founder

Earlier this month, the University of Pennsylvania’s Saar Gill turned up at ASCO to present new data demonstrating that a combination of Imbruvica with Novartis� …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Rising Penn star Saar Gill gets funding for a next-gen CAR-T startup, adding a new weapon to the mix

John Carroll

Editor & Founder

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

New fund will pressure flailing biotechs, as investor frustration boils over

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Ris­ing Penn star Saar Gill gets fund­ing for a next-gen CAR-T start­up, adding a new weapon to the mix

Editor & Founder

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

Rising Penn star Saar Gill gets funding for a next-gen CAR-T startup, adding a new weapon to the mix